Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Vedolizumab, ATC L04AG05 für die Zeit 01.07.2025 - 30.06.2027
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Vedolizumab, ATC L04AG05 für die Zeit 01.07.2025…”. Bids close on 5 May 2027.
The work
Framework discount agreement for Vedolizumab (ATC L04AG05) for German statutory health insurance funds.
- Agreement must be non-exclusive and allow for multiple partners.
Key facts
- Contract period
- 01.07.2025 - 30.06.2027
- Evaluation
- Not a formal procurement procedure; based on meeting submission requirements.
What it takes to qualify
Worth a closer look
- The document states this is not a formal procurement procedure under cartel law, but uses an 'Open Procedure' form for technical reasons.
- The ARGE Vedolizumab is mentioned as the contracting party, but the submission is to DAK-Gesundheit.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- AngebotsschreibenMust include declaration that no exclusion criteria per §§ 123 and 124 GWB apply.
- Anerkennung der vertraglichen Maßgaben der DAK-GesundheitSigned contract with name or company stamp.
- Anlage 1 zum VertragTo be filled out and submitted.
- Anlage 2 zum VertragExcel file listing the medicinal products for the contract.